Xflot
NAVER signs a $1.5 billion AI computing contract with a US inference company for its AI FactoryWindward Bio raises $175 million at $17 in its Nasdaq IPO as Rezera postpones a $200 million dealUS producer prices rise 6.5% over the year to October, the most since November 2022US tells India its goods will get a tariff edge over rivals once Section 301 probes endCisco lifts its hyperscaler AI infrastructure revenue expectation to $9 billion for fiscal 2027Jensen Huang resigns as Nvidia CEO; CFO Colette Kress named interim chiefAnthropic's IPO draws orders for several times the shares on offer at $70–$78Barrick files to list its North American gold assets on the NYSE as American Barrick GoldUS consumer prices rise 0.4% in October; core up 0.3% for a third monthAnthropic sets IPO range at $70–$78 a share for a Nasdaq listing of up to $64.4 billion
Fed funds (effective) 3.88%US 2-year 4.83%US 10-year 5.12%Official rates →

United States · Business news · IPO & Capital Markets · 13 Nov 2026

Windward Bio raises $175 million at $17 in its Nasdaq IPO as Rezera postpones a $200 million deal

US Health Care

AI summary5 points
Read all 5 points
  • Sanofi separately took $50 million of shares and pre-funded warrants, taking expected gross proceeds to $225 million.
  • Rezera postponed its planned $200 million Nasdaq IPO of 16.7 million shares at $11–$13, citing market conditions.
  • Windward paid $70 million upfront for its two licensed programmes, with up to $1.6 billion in milestones.

Written by Claude from this page's own figures at 16 Nov, 06:04 am IST — every number checked against the page. A summary, not advice.

AI summary
  1. Windward Bio priced 10,294,117 shares at $17 on 12 November, the midpoint of its $16–$18 range.
  2. The stock began trading on the Nasdaq Global Select Market as WWB on 13 November.
  3. Sanofi separately took $50 million of shares and pre-funded warrants, taking expected gross proceeds to $225 million.
  4. Rezera postponed its planned $200 million Nasdaq IPO of 16.7 million shares at $11–$13, citing market conditions.
  5. Windward paid $70 million upfront for its two licensed programmes, with up to $1.6 billion in milestones.

Written by Claude from this page's own figures at 16 Nov, 06:04 am IST — every number checked against the page. A summary, not advice.

What happened

Windward Bio priced 10,294,117 shares at $17 on 12 November, the midpoint of its $16–$18 range, and began trading on the Nasdaq Global Select Market as WWB on 13 November. Sanofi separately bought $50 million of shares and pre-funded warrants at the IPO price, taking expected gross proceeds to $225 million before the underwriters' option on 1,544,117 more shares. On the evening of 11 November, Boston-based Rezera, formerly NodThera, postponed its planned $200 million Nasdaq IPO of 16.7 million shares at $11–$13, citing market conditions.

Why it matters for listed companies

The two deals show how selective the US biotech IPO window is: a company with a late-stage asthma antibody and a big-pharma backer priced in its range, while another, with an earlier-stage NLRP3 programme and GSK's indicated interest of up to $25 million, stepped back. Windward paid $70 million upfront for its two licensed programmes, with up to $1.6 billion in milestones, so the IPO money funds trials and licence payments. Banks on both books (Jefferies, TD Cowen) earn fees only on deals that price.

Reported by MLQ.ai — “Sanofi-backed Windward Bio raises $225 million in its Nasdaq IPO as Rezera postpones its listing” ↗ on 13 Nov 2026.

Rates and currencies since this was reported

Official series on 13 Nov 2026 or the last day before it, and the latest observation.

US Treasury 2-year yield
4.88% → 4.83% -5 bp
13 Nov 2026 → 16 Nov 2026 · US Treasury
US Treasury 10-year yield
5.15% → 5.12% -3 bp
13 Nov 2026 → 16 Nov 2026 · US Treasury
Euro in US dollars
1.1052 → 1.1014 -0.0038
13 Nov 2026 → 16 Nov 2026 · ECB reference rate
These figures are measured, not attributed. Prices and rates move for many reasons at once; they show what happened after this story, not that the story caused it. Nothing here is a recommendation to buy, sell or hold.

More on Health Care

All US business stories · Every market · What changed today

Free · one email a day

Market briefs, by country

Pick the markets you follow. Each morning: what changed, in figures — never a tip.

Markets

Free. We email a link to confirm — nothing is sent until you click it. Every brief has a one-click unsubscribe that deletes your record. Data, not advice: XDQ Labs is not registered with SEBI, the US SEC, FINRA or any European regulator. GMP is unofficial. Privacy. Sent daily at 08:15 India time.